Marco Taglietti, Scynexis CEO
April 22, 2022 10:52 AM EDT
R&D
Pharma

Scynex­is builds out case for its an­ti­fun­gal in the hos­pi­tal­ized set­ting, but in­vestors don't seem hap­py

Kyle LaHucik

Senior Reporter

The an­ti­fun­gal work at Scynex­is is not abat­ing. Look­ing to ex­pand be­yond its ini­tial June 2021 nod for treat­ing vagi­nal yeast in­fec­tion, the biotech …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

Cal­tech spin­out de­buts with AI-dri­ven 'mir­ror pep­tide' plat­form

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times